Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios [version 2; referees: 2 approved]

Background: The Portfolio-To-Impact (P2I) Model is a novel tool, developed to estimate minimum funding needs to accelerate health product development from late stage preclinical study to phase III clinical trials, and to visualize potential product launches over time. Methods: A mixed methods approa...

Full description

Bibliographic Details
Main Authors: Robert F Terry, Gavin Yamey, Ryoko Miyazaki-Krause, Alexander Gunn, John C. Reeder
Format: Article
Language:English
Published: F1000 Research Ltd 2018-07-01
Series:Gates Open Research
Online Access:https://gatesopenresearch.org/articles/2-24/v2
_version_ 1818302621838999552
author Robert F Terry
Gavin Yamey
Ryoko Miyazaki-Krause
Alexander Gunn
John C. Reeder
author_facet Robert F Terry
Gavin Yamey
Ryoko Miyazaki-Krause
Alexander Gunn
John C. Reeder
author_sort Robert F Terry
collection DOAJ
description Background: The Portfolio-To-Impact (P2I) Model is a novel tool, developed to estimate minimum funding needs to accelerate health product development from late stage preclinical study to phase III clinical trials, and to visualize potential product launches over time. Methods: A mixed methods approach was used. Assumptions on development costs at each phase were based on clinical trial costs from Parexel’s R&D cost sourcebook. These were further refined and validated by interviews, with a wide variety of stakeholders from Product Development Partnerships, biopharmaceutical and diagnostic companies, and major funders of global health R&D. Results: the tool was used to create scenarios describing the impact, in terms of products developed, of different product portfolios with funding ranging from $1 million per annum through to $500 million per annum. These scenarios for a new global financing mechanism have been previously presented in a report setting out the potential for a new fund for research and development which would assist in accelerating product development for the diseases of poverty.  Conclusion: The P2I tool does enable a user to model different scenarios in terms of cost and number of health products launched when applied to a portfolio of health products.  The model is published as open access accompanied with a user guide.  The design allows it to be adapted and used for other health R&D portfolio analysis as described in an accompanying publication focussing on the pipeline for neglected diseases in 2017. We aim to continually refine and improve the model and we ask users to provide us with their own inputs that can help us update key parameters and assumptions.  We hope to catalyse users to adapt the model in ways that can increase its value, accuracy, and applications.
first_indexed 2024-12-13T05:41:49Z
format Article
id doaj.art-2e8e247f493e4960862f2b055021244e
institution Directory Open Access Journal
issn 2572-4754
language English
last_indexed 2024-12-13T05:41:49Z
publishDate 2018-07-01
publisher F1000 Research Ltd
record_format Article
series Gates Open Research
spelling doaj.art-2e8e247f493e4960862f2b055021244e2022-12-21T23:57:46ZengF1000 Research LtdGates Open Research2572-47542018-07-01210.12688/gatesopenres.12816.213921Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios [version 2; referees: 2 approved]Robert F Terry0Gavin Yamey1Ryoko Miyazaki-Krause2Alexander Gunn3John C. Reeder4The Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, 1211, SwitzerlandCenter for Policy Impact in Global Health, Duke Global Health Institute, Durham, NC, 27710, USAThe Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, 1211, SwitzerlandCenter for Policy Impact in Global Health, Duke Global Health Institute, Durham, NC, 27710, USAThe Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, 1211, SwitzerlandBackground: The Portfolio-To-Impact (P2I) Model is a novel tool, developed to estimate minimum funding needs to accelerate health product development from late stage preclinical study to phase III clinical trials, and to visualize potential product launches over time. Methods: A mixed methods approach was used. Assumptions on development costs at each phase were based on clinical trial costs from Parexel’s R&D cost sourcebook. These were further refined and validated by interviews, with a wide variety of stakeholders from Product Development Partnerships, biopharmaceutical and diagnostic companies, and major funders of global health R&D. Results: the tool was used to create scenarios describing the impact, in terms of products developed, of different product portfolios with funding ranging from $1 million per annum through to $500 million per annum. These scenarios for a new global financing mechanism have been previously presented in a report setting out the potential for a new fund for research and development which would assist in accelerating product development for the diseases of poverty.  Conclusion: The P2I tool does enable a user to model different scenarios in terms of cost and number of health products launched when applied to a portfolio of health products.  The model is published as open access accompanied with a user guide.  The design allows it to be adapted and used for other health R&D portfolio analysis as described in an accompanying publication focussing on the pipeline for neglected diseases in 2017. We aim to continually refine and improve the model and we ask users to provide us with their own inputs that can help us update key parameters and assumptions.  We hope to catalyse users to adapt the model in ways that can increase its value, accuracy, and applications.https://gatesopenresearch.org/articles/2-24/v2
spellingShingle Robert F Terry
Gavin Yamey
Ryoko Miyazaki-Krause
Alexander Gunn
John C. Reeder
Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios [version 2; referees: 2 approved]
Gates Open Research
title Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios [version 2; referees: 2 approved]
title_full Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios [version 2; referees: 2 approved]
title_fullStr Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios [version 2; referees: 2 approved]
title_full_unstemmed Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios [version 2; referees: 2 approved]
title_short Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios [version 2; referees: 2 approved]
title_sort funding global health product r d the portfolio to impact model p2i a new tool for modelling the impact of different research portfolios version 2 referees 2 approved
url https://gatesopenresearch.org/articles/2-24/v2
work_keys_str_mv AT robertfterry fundingglobalhealthproductrdtheportfoliotoimpactmodelp2ianewtoolformodellingtheimpactofdifferentresearchportfoliosversion2referees2approved
AT gavinyamey fundingglobalhealthproductrdtheportfoliotoimpactmodelp2ianewtoolformodellingtheimpactofdifferentresearchportfoliosversion2referees2approved
AT ryokomiyazakikrause fundingglobalhealthproductrdtheportfoliotoimpactmodelp2ianewtoolformodellingtheimpactofdifferentresearchportfoliosversion2referees2approved
AT alexandergunn fundingglobalhealthproductrdtheportfoliotoimpactmodelp2ianewtoolformodellingtheimpactofdifferentresearchportfoliosversion2referees2approved
AT johncreeder fundingglobalhealthproductrdtheportfoliotoimpactmodelp2ianewtoolformodellingtheimpactofdifferentresearchportfoliosversion2referees2approved